Screening of ATTRwt in Patient With Advanced AV-Block Undergoing Pacemaker Implantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

170 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-10-01

Study Completion Date

2025-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators will nationally investigate the prevalence of Transthyretin Amyloidosis wildtype (ATTRwt) in patients of ≥ 65 years with left ventricular hypertrophy who present with high degree atrioventricular block (AV-block) and are admitted for pacemaker implantation. The investigators aim to characterize the group of patients with positive screening of ATTR and compare the ATTRwt disease stage at time of diagnosis for patients identified with ATTR at screening with a control group of routinely clinically diagnosed ATTRwt patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Danish Randomized Trial on Leadless vs Transvenous Pacing

NCT05856799

AV Block

RECRUITING NA

Restoration of Atrioventricular Synchrony Trial

NCT01275833

First Degree AV Block

TERMINATED NA

An Arrhythmia Risk Stratification and Genetic Trial

NCT01209494

Cardiomyopathies, Primary Arrhythmia Sudden Cardiac Death +1 more

COMPLETED

The Role of hs Troponin I and NT-proBNP in Predicting Atrial Fibrillation in Patients With Permanent Pacemakers

NCT06174506

Atrial Fibrillation

RECRUITING

Central Haemodynamics and Pacing for AV Block

NCT07276490

Atrioventricular Block Pacing Therapy Right Ventricular Pacing +1 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloid Cardiomyopathy Block, AV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amyloidosis Screening

Patients fulfilling eligibility criteria will screened for Cardiac Amyloidosis.

Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)

Intervention Type DIAGNOSTIC_TEST

Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.

DPD-scintigraphy. (Echocardiography)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amyloidosis screening (bloodtest, DPD-scintigraphy, potentially endomyocardial biopsy)

Bloodtest: Troponin I, NT-pro-BNP, electrolyte status, renal function, kampda/lambda free chain + ratio, M-komponent.

DPD-scintigraphy. (Echocardiography)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men ≥65years or women ≥75years with unexplained AV-block with pacemaker indication, as decided per treating physician and presence of left ventricular hypertrophy ≥12mm.

Exclusion Criteria

* Reversible causes for AV-block, som as AV-node disturbing medicament, ion-disturbances, hypothyroidism, hypoxia, ischemia, new heart surgery \<1month, endocarditis.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No